Proficio Capital Partners LLC Takes $584,000 Position in Biogen Inc. $BIIB

Proficio Capital Partners LLC acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,701 shares of the biotechnology company’s stock, valued at approximately $584,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Nwam LLC increased its holdings in Biogen by 123.8% during the 2nd quarter. Nwam LLC now owns 2,553 shares of the biotechnology company’s stock worth $552,000 after purchasing an additional 1,412 shares in the last quarter. Rehmann Capital Advisory Group lifted its holdings in shares of Biogen by 6.1% in the second quarter. Rehmann Capital Advisory Group now owns 1,236 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 71 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in shares of Biogen by 15.8% during the second quarter. Alyeska Investment Group L.P. now owns 932,374 shares of the biotechnology company’s stock worth $201,449,000 after buying an additional 127,324 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Biogen by 3.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 7,299 shares of the biotechnology company’s stock worth $1,577,000 after buying an additional 253 shares in the last quarter. Finally, Wedbush Securities Inc. grew its holdings in shares of Biogen by 5.1% during the second quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after buying an additional 56 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Up 3.1%

NASDAQ:BIIB opened at $222.67 on Thursday. Biogen Inc. has a twelve month low of $135.39 and a twelve month high of $225.59. The firm has a market capitalization of $32.90 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 2.39 and a beta of 0.17. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average price is $208.99 and its two-hundred day moving average price is $196.25.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI SC-AI, Eisai and Biogen’s once-weekly subcutaneous autoinjector for patients with mild cognitive impairment or mild Alzheimer’s disease dementia. The at-home treatment provides an alternative to biweekly hospital infusions, potentially improving patient adherence, reducing clinic visits and lowering healthcare-resource requirements. China represents a substantial long-term market, with an estimated 17 million people affected by early Alzheimer’s disease in 2024. Launch is planned during Eisai’s fiscal 2026. China approval of LEQEMBI SC-AI
• Positive Sentiment: Zorevunersen data supported pipeline optimism. Four-year follow-up in Dravet syndrome showed durable seizure reductions and sustained cognitive and behavioral improvements, with a generally well-tolerated safety profile. Completion of enrollment in the Phase 3 EMPEROR study adds a meaningful late-stage development milestone for Biogen’s partnered pipeline. Zorevunersen clinical data
• Positive Sentiment: Commercial sentiment around LEQEMBI improved after Canada’s drug agency issued a positive recommendation supporting public reimbursement for eligible early-Alzheimer’s patients. Recent analyst target increases also reinforced expectations for LEQEMBI uptake and Biogen’s transition toward newer growth assets. Canada LEQEMBI reimbursement recommendation
• Neutral Sentiment: Biogen completed its acquisition of RayThera to expand into small-molecule immunology therapies. The lead program has only recently entered Phase 1, so the deal offers strategic diversification but carries clinical, execution and financial risks before it can contribute material revenue. Biogen RayThera acquisition

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of recent research reports. Mizuho upped their price target on Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. TD Cowen lifted their price objective on shares of Biogen from $215.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating on shares of Biogen in a research report on Tuesday, July 14th. Bank of America reduced their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a report on Tuesday, July 21st. Finally, Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $227.79.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.